Leiomyosarcoma Pipeline Booms as 10+ Therapies Likely to Enter the Treatment Domain

DelveInsight's, "Leiomyosarcoma Pipeline Insight, 2023," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Leiomyosarcoma pipeline landscape. It covers the Leiomyosarcoma pipeline drug profiles, including Leiomyosarcoma clinical trials and nonclinical stage products. It also covers the Leiomyosarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

For Leiomyosarcoma emerging drugs, the Leiomyosarcoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Leiomyosarcoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

In the Leiomyosarcoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Leiomyosarcoma clinical trials studies, Leiomyosarcoma NDA approvals (if any), and product development activities comprising the technology, Leiomyosarcoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Key takeaways from the Leiomyosarcoma Pipeline Report

• Over 10+ Leiomyosarcoma companies are evaluating 10+ Leiomyosarcoma pipeline therapies in various stages of development, and their anticipated acceptance in the Leiomyosarcoma market would significantly increase market revenue.

• The leading Leiomyosarcoma Companies include Merck, Advenchen Laboratories, Merck Sharp & Dohme LLC, Trillium Therapeutics, PTC Therapeutics, Johnson & Johnson, Philogen, EMD Serono, BioAtla, Inc., Incyte Corporation, Clovis Oncology, Inc., PharmaMar, and others.

• Promising Leiomyosarcoma Pipeline Therapies include Trabectedin, Dacarbazine, Unesbulin, Dacarbazine, Yondelis, Dexamethasone, Gemcitabine, Rucaparib, Nivolumab, AL3818, Dacarbazine, ARQ 501, letrozole, and others.

• The Leiomyosarcoma companies and academics are working to assess challenges and seek opportunities that could influence Leiomyosarcoma R&D. The Leiomyosarcoma pipeline therapies under development are focused on novel approaches to treat/improve Leiomyosarcoma.

To explore more information on the latest breakthroughs in the Leiomyosarcoma Pipeline treatment landscape of the report, click here @ Leiomyosarcoma Pipeline Outlook- https://www.delveinsight.com/sample-request/leiomyosarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Leiomyosarcoma Overview
Leiomyosarcoma, or LMS, is a type of rare cancer that grows in the smooth muscles. The smooth muscles are in the hollow organs of the body, including the intestines, stomach, bladder, and blood vessels. In females, there is also smooth muscle in the uterus. These smooth muscle tissues help move blood, food, and other material through the body and work without you being aware. LMS is an aggressive cancer, which means it can grow quickly. LMS is found most often in the abdomen or in the uterus. LMS is a type of soft tissue sarcoma and makes up between 10% to 20% of soft tissue sarcoma cases. LMS is more common in adults than children. It is estimated that only about 20 to 30 children are diagnosed with LMS in the United States per year. LMS of the uterus affects about 6 per 1 million people per year in the United States.

Recent Developmental Activities in the Leiomyosarcoma Treatment Landscape

• In November 2014, Merck and Pfizer announced a strategic alliance to co-develop and co-commercialize BAVENCIO. Currently, it is in Phase II stage of clinical trial evaluation to treat Leiomyosarcoma.

• AL3818 is a novel small molecule PTK inhibitor being developed by Advenchen Laboratories. Advenchen Laboratories is conducting a Phase III study to evaluate the safety and efficacy of AL3818 (anlotinib) hydrochloride in the treatment of metastatic or advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), and synovial sarcoma (SS).

For further information, refer to the detailed Leiomyosarcoma Unmet Needs, Leiomyosarcoma Market Drivers, and Leiomyosarcoma Market Barriers, click here for Leiomyosarcoma Ongoing Clinical Trial Analysis @ https://www.delveinsight.com/sample-request/leiomyosarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Leiomyosarcoma Emerging Drugs Profile

• BAVENCIO® (avelumab): Merck
BAVENCIO is a human anti-programmed death ligand-1 (PD-L1) antibody. BAVENCIO has been shown in preclinical models to engage both the adaptive and innate immune functions. By blocking the interaction of PD-L1 with PD-1 receptors, BAVENCIO has been shown to release the suppression of the T cell-mediated antitumor immune response in preclinical models.10-12 In November 2014, Merck and Pfizer announced a strategic alliance to co-develop and co-commercialize BAVENCIO. Currently, it is in Phase II stage of clinical trial evaluation to treat Leiomyosarcoma.

• AL-3818: Advenchen Laboratories
AL3818 is a novel small molecule PTK inhibitor being developed by Advenchen Laboratories. Advenchen Laboratories is conducting a Phase III study to evaluate the safety and efficacy of AL3818 (anlotinib) hydrochloride in the treatment of metastatic or advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), and synovial sarcoma (SS).

Leiomyosarcoma Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Leiomyosarcoma. The companies which have their Leiomyosarcoma drug candidates in the most advanced stage, i.e. phase III include, Advenchen Laboratories.

Request a sample and discover the recent advances in Leiomyosarcoma Ongoing Clinical Trial Analysis and Medications, click here @ Leiomyosarcoma Treatment Landscape- https://www.delveinsight.com/sample-request/leiomyosarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Leiomyosarcoma Pipeline Report

• Coverage- Global

• Leiomyosarcoma Companies- Merck, Advenchen Laboratories, Merck Sharp & Dohme LLC, Trillium Therapeutics, PTC Therapeutics, Johnson & Johnson, Philogen, EMD Serono, BioAtla, Inc., Incyte Corporation, Clovis Oncology, Inc., PharmaMar, and others.

• Leiomyosarcoma Pipeline Therapies- Trabectedin, Dacarbazine, Unesbulin, Dacarbazine, Yondelis, Dexamethasone, Gemcitabine, Rucaparib, Nivolumab, AL3818, Dacarbazine, ARQ 501, letrozole, and others.

• Leiomyosarcoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Dive deep into rich insights for drugs for Leiomyosarcoma Market Drivers and Leiomyosarcoma Market Barriers, click here @ Leiomyosarcoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/leiomyosarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Leiomyosarcoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Leiomyosarcoma - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Leiomyosarcoma Collaboration Deals
9. Late Stage Products (Phase III)
10. AL-3818: Advenchen Laboratories
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. BAVENCIO® (avelumab): Merck
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Drug Name: Company Name
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Leiomyosarcoma Key Companies
20. Leiomyosarcoma Key Products
21. Leiomyosarcoma- Unmet Needs
22. Leiomyosarcoma- Market Drivers and Barriers
23. Leiomyosarcoma- Future Perspectives and Conclusion
24. Leiomyosarcoma Analyst Views
25. Leiomyosarcoma Key Companies
26. Appendix

Got Queries? Find out the related information on Leiomyosarcoma Mergers and acquisitions, Leiomyosarcoma Licensing Activities @ Leiomyosarcoma Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/leiomyosarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.